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High density lipoprotein (HDL) cholesterol changes were 
followed in 45 men with coronary heart disease who under-
went 12 weeks of monitored aerobic exercise. Twenty-five 
patients who were taking a nonselective beta-receptor 
blocking drug (Group 1) did not demonstrate a significant 
change in HDL cholesterol after exercise (mean difference 
2.8 ± 11.5 mg/dl), whereas patients who had not received a 
beta-blocking drug for ::::::3 months (Group 2) showed a 
significant increase (mean difference 8.4 ± 5.5 mg/dl; p < 
0.05). However, for those patients in each group who had 
an initial HDL cholesterol level <35 mg/dl before exercise, 
there was a significant increase in HDL cholesterol levels 
(mean difference 8 ± 6.9 mg/dl [p < 0.02] and 11 ± 3 mg/ 
dl [p < 0.001] for Group 1 and Group 2, respectively) and 
a significant decrease in the low density lipoprotein (LDL)/ 
Most selective and nonselective beta]-adrenergic blocking 
drugs adversely affect serum high density lipoprotein (HDL) 
cholesterol and triglyceride concentrations (1,2). This is a 
potentially harmful side effect since HDL cholesterol is now 
known to be an important independent risk factor for the 
development of coronary artery disease (3). Physical activ-
ity, on the other hand, tends to elevate HDL cholesterol 
levels in both normal subjects and patients with coronary 
artery disease (4-9). The importance of increasing the HDL 
cholesterol level was demonstrated in the recent Helsinki 
Heart Study (10), which showed that an increase in HDL 
cholesterol by > 10% reduces future coronary events by 
34%. It is not known whether the HDL cholesteroi-lowering 
properties of betal-blocking agents prevent the expected 
increase of this lipoprotein after long-term exercise. We 
therefore compared the lipid profile changes after comple-
tion of a 12 week monitored aerobic exercise program in 
From the University of Pittsburgh School of Medicine and Montefiore 
Hospital, 3459 Fifth Avenue, Pittsburgh, Pennsylvania. 
Manuscript received December 24, 1987; revised manuscript received 
March 16, 1988, accepted April 8, 1988. 
Address for reprints: Stephen Arvan, MD, Department of Cardiology, 
Veterans Administration, Uriiversity Drive C, Pittsburgh, Pennsylvania 
15240. 
©1988 by the American College of-Cardiology 
HDL cholesterol ratio (mean difference -1.2 ± 1.6 [p < 
0.05] and -0.9 ± 0.57 [p < 0.001], respectively). Patients 
in both groups who started exercise with an HDL choles-
terollevel >35 mg/dl did not show a significant change after 
exercise. 
Patients in Groups 1 and 2 achieved similar levels of 
exercise training after 12 weeks and were closely matched 
in age, medications, alcohol intake and smoking. The 
results indicate that among high risk patients (with an 
abnormally low HDL cholesterol level) exercise training can 
induce an augmentation of HDL cholesterol in those receiv-
ing a beta-blocking drug similar to that of patients not 
receiving such a drug. 
(J Am Coli Cardiol1988;12:662-8) 
patients with coronary artery disease who were or were not 
receiving a nonselective beta-blocker during the program. 
Methods 
Study patients. Fifty-five men aged 39 to 75 years (mean 
62.6 ± 9) with a recent history of myocardial infarction 
(within 1 month) or nonsurgically correctable angina pectoris 
were consecutively enrolled into a phase II cardiac rehabil-
itation program after referral by their local medical physi-
cian. Patients with symptomatic congestive heart failure, 
significant pulmonary disease, unstable arrhythmia, periph-
eral vascular disease or severe hypertension were excluded 
from the study. Ten of these subjects were not included in 
the final study group because of left bundle branch block on 
the surface electrocardiogram (ECG) (n = 2), change in 
cardiac medication during the training period (n = 3), 
intervening acute myocardial infarction or coronary artery 
bypass surgery (n = 1), and failure to complete the program 
or attend ::::::75% of the sessions offered (n = 4). Twenty-five 
subjects had been receiving for ::::::4 weeks before entry into 
the study a nonselective beta-receptor blocking agent with 
no change in dose (Group O. Twenty patients had not 
received a beta-blocker for ::::::3 months before the study. 
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All participants were placed on a Phase I American Heart 
Association diet 4 weeks before initiation of the exercise 
program and kept on a constant composition, isoweight diet. 
The composition was 30% fat, 15% protein, 55% carbohy-
drate and 300 mg/day cholesterol. The total daily caloric 
requirements are estimated on the basis of energy expendi-
ture at rest and predicted activity level. A diary of alcoholic 
intake and cigarette smoking was kept by each patient and a 
dietary history was taken on a weekly basis. To measure 
compliance with the diet, the patients were weighed regu-
larly and anthropometric data were obtained monthly. Skin-
fold thickness was measured by Harpenden calipers. The 
percent of body fat was predicted from the sum of biceps, 
triceps, subscapular and suprailiac readings (11). Percent 
body fat is derived from the nomogram of Brozek and Keys 
(12), which assumes that the density of lean tissue is con-
stant for both genders and all ages. 
Treadmill exercise test. Treadmill exercise testing was 
performed twice within a 3 week period before entry into the 
study and then monthly during and at the end of the 
rehabilitation period. A standard Bruce protocol was fol-
lowed with the patient in a fasting state. A continuous 12 
lead ECG was obtained throughout the test and recovery 
periods. The ECG data were computer-processed by a 
Marquette Electronic Data Loggers. All exercise tests were 
symptom-limited efforts, except when there was a horizontal 
or downward ST segment depression 2:0.3 m V, a life-
threatening arrhythmia or a >20 mm Hg decrease in systolic 
blood pressure associated with ST segment depression. 
Horizontal or downs loping ST segment depression 2: 1 mm 
that lasted 2:3 min into the recovery period was considered 
abnormal. 
Oxygen uptake CV02) and carbon dioxide output before 
and during exercise were determined from the measurement 
of oxygen (with a paramagnetic oxygen analyzer) in the 
expired air using a Gould 2900 Energy Measurement Mod-
ule. Expired volumes were determined by a mass flow 
meter. The metabolic cart was integrated with an Epson 
computer programmed to calculate oxygen consumption and 
carbon dioxide production continuously by breath by breath 
analysis, and at the point of maximal exercise (peak V02). 
Values were obtained every 20 s during baseline (2 min), 
warm-up (1 min) and exercise periods. Peak exercise oc-
curred at the sign- or symptom-limited end point. 
Serum lipid measurements. Blood was drawn on four 
occasions after a 12 to 14 h fast; three times before entry into 
the study and once at the end of the exercise program. 
Because the variability of individual determinations was 
insignificant, the last preentry lipid value (third blood sample 
drawn) was used for comparison with the postexercise level. 
Total cholesterol, HDL cholesterol and triglycerides were 
directly measured by an enzymatic cholesterol assay method 
adapted to the Technicon Auto A analyzer II continuous-
flow analytical instrument (13). Total cholesterol was mea-
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sured by using cholesterol esterase (>440 Ulliter) to remove 
cholesterol from its esters and then oxidizing the free cho-
lesterol with cholesterol oxidase (>500 U/liter) to produce 
hydrogen peroxide. The resulting indicator dye can be 
quantitated photometrically. High density lipoprotein cho-
lesterol was determined similarly, except that serum low 
density and very low density lipoproteins were first selec-
tively precipitated by a reagent containing 9.7 mmolliiter 
phosphotungstate, 0.4 molliiter magnesium ions, and 0.08% 
sodium azxide (preservative). The soluble HDL cholesterol 
fraction was then measured after the enzymatic steps for 
cholesterol determination. 
The method of determining triglyceride levels depends on 
measuring glycerol liberated from lipase-induced hydrolysis 
of triglycerides. Through a series ofreactions using glycerol 
kinase, pyruvate kinase, and lactate dehydrogenase, re-
duced nicotinamide adenine dinucleotide is oxidized to nic-
otinamide adenine dinucleotide (reduced) (NADH). Triglyc-
eride levels can be quantitated by relating the hydrolysis of 
1 mole of triglyceride molecule for every mole of NADH 
oxidized in the final reaction. Assay controls, both normal 
and abnormal, are performed eight times a year through the 
College of American Pathologists for comprehensive evalu-
ation. For the past year the variability of triglycerides, total 
cholesterol and HDL cholesterol was 0-0.8 (±SD), 0.1-1.8 
(±SD), and 0.8-1.6 (±SD), respectively. A standard devia-
tion (SD) of ±2 is considered accurate. Low density lipo-
protein (LDL) cholesterol levels were calculated from the 
total cholesterol and HDL cholesterol determination as 
described by Friedwald et al. (14). 
Exercise program. The 12 week program consists of 30 to 
45 min sessions of pedaling a stationary bicycle (Monark 
model 668), walking on a treadmill (Marquette) or using an 
arm ergometer (Monark) three times a week under nurse 
supervision and ECG telemetry. The initial training intensity 
is set at 50 to 75% of the peak oxygen consumption (PV02) 
level attained on exercise testing. This was progressively 
increased during the first month of the training program so 
that all subjects reached 70 to 85% of peak V02 at the end of 
2 weeks. An exercise stress test was repeated every month 
and training conditions for the subsequent month were 
adjusted accordingly for each subject. In each session, 
exercise was preceded by a 10 min warm-up period and 
followed by a 10 to 15 min cooling down period. 
The end points for a training response, as determined by 
a treadmill stress test, were an alteration in time of exercise, 
heart rate, blood pressure and rate-pressure product for 
sub maximal exercise at the end of the first stage of exercise, 
and peak V02 taken as the average of the last two 20 s values 
just before the test was ended. 
Statistics. All data are reported as mean ±SD. The un-
paired Student's t test was used for comparisons between 
groups and a paired Student's t test was used to compare 
pre- and post-exercise data within the same group. The 
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Table 1. Comparison of Clinical Variables in Patients Taking 
(Group 1) and Not Taking (Group 2) a Beta-Blocking Drug 
Group 1 Group 2 
No. of patients 25 20 
Age (yr) 62 ± 8 63 ± 12 
Weight (kg) 
Pre 79 ± 11 76 ± 15 
Post 79 ± 13 78 ± 9 
Body fat (%) 
Pre 21 ± 5 22 ± 2 
Post 21 ± 4 22 ± 4 
Diuretics 0 1 
Calcium channel blocker 4 2 
ETOH (oz/week) 3.2 ± 4 4.0 ± 2.4 
Smokers 0 0 
EF(%) 45 ± 12 47 ± 18 
Values are expressed as mean values ± SD. EF = ejection fraction 
(radionuclide); ETOH = alcohol consumption; Pre and Post = before and 
after exercise. 
required level of significance was a p value of <0.05. 
Covariate analysis using the general linear models procedure 
was carried out to assess the independent change of HDL 
cholesterol after controlling for triglycerides (15). 
Results 
Clinical data (Table 1). Group 1 patients were those who 
were taking a constant dose of a nonselective beta1-
adrenergic blocking agent before and during the exercise 
program. Each individual had been taking a beta-blocking 
drug for ;:::4 weeks before starting the exercise rehabilitation 
program. Group 2 patients were those postmyocardial in-
farction patients who had not received a beta-blocker for ;:::3 
months. There were 25 men in Group 1 with a mean age of 62 
± 8 years, and 20 men in Group 2 with a mean age of 63 ± 
l2 years. The attendance rate was 95 ± 3.3% for Group 1 and 
96 ± 2% for Group 2. The average sustained heart rate 
during the 36 training sessions was, respectively, 81 ± 7.2% 
and 84 ± 4.2% of the target heart rate for Group 1 and Group 
2 patients. Alcohol consumption, smoking history and 
preentry ejection fraction were similar for both groups, as 
were pre- and post-exercise weight and percent body fat 
groups. One patient in Group 2 was being treated with a 
diuretic during the exercise program. 
Exercise data (Table 2). Table 2 indicates that there was a 
comparable improvement of the variables related to training 
effect in the two groups. The time of exercise and peak \102 
increased, whereas the heart rate at submaximal exercise 
decreased. The heart rate at rest and during peak exercise 
was significantly lower in Group 1 than in Group 2. This 
difference indicates the effectiveness of beta-adrenergic 
blockade in Group 1 patients. 
Lipid data (Tables 3 and 4). The lipid profile for Group 1 
JACC Vol. 12, No.3 
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Table 2. Comparison of Exercise Training Variables in Patients 
Taking (Group 1) and Not Taking (Group 2) a Beta-Blocking Drug 
Group 1 (p) Group 2 (p) 
Time (min) 
Pre 6±2 5 ± 3 
Post 9 ± 3 <0.001 8 ± 3 <0.002 
a Time 5 ± 10 3 ± 2 
PV02 (mVmin per 
kg) 
Pre 24 ± 5 22 ± 7 
Post 35 ± 10 <0.001 32 ± 10 <0.01 
apvo2 12 ± 8 10 ± 9 
SM HR (beats/min) 
Pre 121 ± 6 137 ± 15 
Post 116 ± 6 <0.01 123 ± 18 <0.001 
aSMHR -10 ± 24 -11 ± 14 
Group 1 Versus Group 2 
Rest HR (beats/min) 
Pre 63 ± 8.4 79 ± 13 <0.001 
Post 63 ± 10 79 ± 10 <0.001 
Peak ex HR 
(beats/min) 
Pre 123 ± 26 139 ± 15 <0.05 
Post 121 ± 16 137 ± 20 <0.05 
Values are expressed as mean values ± SD. PV02 = peak oxygen 
consumption during exercise; a = mean of differences pre- and postexercise; 
ex = exercise; SM HR = submaximal heart rate before (Pre) and after (Post) 
exercise. 
and Group 2 patients in Table 3 indicates that the total 
cholesterol, LDL cholesterol and triglycerides were not 
significantly altered in either group after completion of the 
program. However, the HDL cholesterol level increased 
significantly in Group 2 (mean change 8.4 ± 5.5 mg/dl; p < 
0.05), whereas the change was insignificant in Group 1 (mean 
change 2.8 ± 11.5) after exercise conditioning. The LDLI 
HDL ratio decreased significantly only in Group 2 patients 
(-0.56 ± 0.7; p < 0.01). There was also no significant 
difference in lipid values between Groups 1 and 2 before the 
training program. 
The HDL cholesterol response to exercise was further 
examined by subgrouping patients into those who had an 
initial abnormally low HDL cholesterol «35 mg/dl) and 
those who had a level within the normal range before the 
exercise program (Table 4). A level of 35 mg/dl was chosen 
because this is the approximate lower limit of normal for 
middle- and older-aged men in the Framingham study (3). 
Both Group 1 and Group 2 patients with an abnormally low 
preexercise HDL cholesterol level showed a significant 
improvement after exercise (mean increase 8 ± 6.9 mg/dl [p 
< 0.02] and 11 ± 3 [p < 0.001] for Group 1 and Group 2, 
respectively). Covariant analysis controlling for triglycerides 
indicated that the improvement of HDL cholesterol re-
mained just as significant before controlling for triglyceride 
JACC Vol. 12, No.3 
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Table 3. Lipid Profile in Patients Taking (Group l) and Not Taking (Group 2) a Beta-Blocking Drug 
TC HDL-C LDL-C Triglycerides LDLlHDL 
Group 1 
Pre 260 ± 153 36 ± 13 181 ± 48 208 ± 130 5.2 ± 2 
Post 256 ± 55 39 ± 12 177 ± 58 186 ± 177 5.9 ± 2 
Jl -4.3 ± 38 2.8 ± 11.5 -3.5 ± 36 -17 ± 101 -0.31 ± 2 
p NS NS NS NS NS 
Group 2 
Pre 249 ± 44 36 ± 10.5 165 ± 41 233 ± 245 4.6 ± 1.4 
Post 253 ± 41 45 ± 11 178 ± 39 130 ± 86 4.0 ± 1.2 
Jl 14 ± 21 8.4 ± 5.5 14 ± 17.5 -90 ± 172 -0.56 ± 0.7 
p NS <0.05 NS NS <0.01 
Group 1 versus Group 2 
Pre (p) NS NS NS NS NS 
Values are expressed as mean values ± SD. HDL-C = high density lipoprotein cholesterol (mg/dl); LDL-C = low 
density lipoprotein cholesterol (mg/dl); TC = total cholesterol (mg/dl); other abbreviations as in Tables I and 2. 
(p < 0.05 for adjusted means), and that increases of HDL 
cholesterol occurred independently of triglyceride changes 
(F = 0.35, p < 0.05). There was also an insignificant 
difference of triglyceride levels in groups with normal as 
compared with low HDL cholesterol, and there was no 
significant change in triglyceride levels before and after 
exercise in these subgroups. Conversely, when Group 1 and 
Group 2 patients were designated into low « 150 mg/dO and 
normal-high (> 150 mg/dl) triglyceride subgroups, there were 
no significant changes in triglycerides or HDL cholesterol 
levels after exercise except in Group 2 subjects who entered 
the study with a high baseline triglyceride level (296.6 ± 283 
mg/dl). In this group there was a significant increase in HDL 
cholesterol (31 ± 4.4 to 39 ± 4 mg/dl pre- and postexercise, 
respectively; p < 0.001). However, the degree of triglyceride 
reduction after exercise for this subgroup did not reach 
statistical significance (169 ± 151 mg/dl postexercise, p > 
0.05). 
Patients whose initial HDL cholesterol level was in the 
normal range did not show a significant change after fin-
ishing the program (-4.1 ± 9.5 and 4.8 ± 5 mg/dl, respec-
tively for Group 1 and Group 2). The LDLlHDL ratio 
decreased significantly in the subgroups who had an abnor-
mally low HDL cholesterol at the start of the exercise 
program, but did not change for those patients with an initial 
HDL cholesterol value within the normal range (Table 4). 
There were no significant differences in the preexercise lipid 
values between Groups 1 and 2. 
Discussion 
Beta-blocking agents reduce HDL cholesterol, increase 
serum triglycerides and increase the cholesterol ratio (1,14). 
It is not clear whether these same changes persist during 
long-term exercise in subjects prone to coronary disease or 
those who have known coronary artery obstruction. During 
Table 4. Changes in HDL-Cholesterol Levels After Exercise Based on Initial Low or Normal Values for Groups 1 and 2 
Low HDL-C HDL-C 
«35 mg/dl) LDLlHDL Triglycerides (>35 mg/dl) LDLlHDL Triglycerides 
Group 1 
No. of patients 14 11 
Pre 26.8 ± 3 6.1 ± 2.3 221.1 ± 170 45.6 ± 11.5 4.2 ± 1.I 191 ± 74 
Post 35.8 ± 11 5.0 ± 1.8 194.5 ± 86 41.6 ± 12 4.8 ± 2.1 176.6 ± 95 
Jl 8.0 ± 7 -1.2 ± 1.6 -26.5 ± 126 -4.1 ± 9.5 0.56 ± 1.4 -15.0 ± 83 
(p) <0.02 <0.05 NS NS NS NS 
Group 2 
No. of patients 11 9 
Pre 30.1 ± 3 5.2 ± 1 304.3 ± 300 47.2 ± 8 3.7 ± 0.9 126.7 ± 46 
Post 41.0 ± 5 4.4 ± 0.9 170.2 ± 100 52.0 ± 12 3.6 ± 1.3 104.8 ± 38 
Jl 11.0 ± 3 -0.9 ± 0.57 -134.0 ± 212 4.8 ± 5 -0.1 ± -21.0 ± 36 
(p) <0.001 <0.001 NS NS NS NS 
Group 1 versus Group 2 
Pre (p) NS NS NS NS NS NS 
Abbreviations as in Table 3. 
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acute exercise, nonselective beta-blockers attenuate the 
expected temporary increase of HDL cholesterol (16). The 
purpose of the present study was to determine whether 
beta-blockers also prevent the expected increase in HDL 
cholesterol in patients with coronary artery disease during 
long-term exercise. 
Blood lipids and exercise. The HDL cholesterol level for 
all Group 1 patients (those taking a beta-blocker) did not 
change significantly after the 12 week aerobic conditioning 
program. In contrast, Group 2 patients (those not taking a 
beta-blocker) had a statistically significant increase in HDL 
cholesterol (20%) after completion of the same exercise 
program. The latter response was expected because HDL 
cholesterol is known to increase in highly trained athletes 
(17-19) as well as in subjects with coronary artery disease 
who have participated in a cardiac rehabilitation program (4-
9). Our findings therefore appear to support the results of 
others that suggest that beta-adrenergic blocking drugs mod-
ify the expected improvement in HDL cholesterol after 
long-term exercise (20-22). 
It is generally accepted that the patients who have the 
lowest baseline HDL cholesterol level tend to show the 
greatest change after exercise (23-25). For Group 1 and 
Group 2 patients who had initial HDL cholesterol level <35 
mg/dl (3), there was a significant change not only in HDL 
cholesterol level (increase) but also in the LDLlHDL ratio 
(decrease). Within this subgroup, augmentation of the HDL 
cholesterol level after exercise was similar in patients receiv-
ing a beta-blocker (26%) and in those not receiving a 
beta-blocker (27%). In contrast, when the preexercise HDL 
cholesterol level was in the normal range (> 35 mg/dl), there 
was no significant increase after long-term exercise in either 
group. These findings indicate that HDL cholesterol tends to 
increase after exercise primarily in subjects with levels 
below the 20th percentile (26,27) in whom the potential for 
developing additional coronary events is extremely high. In 
addition, nonselective beta-blocking drugs do not interfere 
with the improvement in HDL cholesterol levels in these 
types of patients. Previous preliminary studies (20-22) have 
not addressed the lipid responses to exercise in the highest 
risk individuals who are taking a beta-blocking agent. These 
individuals may in fact benefit from an exercise training 
program despite taking a drug that usually lowers HDL 
cholesterol. 
Exercise conditioning. Both groups were well matched in 
age, gender, smoking, alcohol consumption and diet. The 
body weight and percent of body fat did not alter signifi-
cantly from the preentry values. Both groups demonstrated 
a comparable positive exercise training effect from the 12 
week program. The exercise variables that most consistently 
indicate a training effect in our program are the time of 
exercise, peak Y02, and the heart rate at a matched submax-
imal exercise level. Despite reports to the contrary (28,29), 
beta-blocking agents did not prevent a training effect. Group 
JACC Vol. 12. No.3 
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1 patients performed just as well as Group 2 patients despite 
a lower heart rate at rest and a lower peak exercise heart 
rate. This response is consistent with other reports (30-33) 
indicating that patients receiving beta-blockers may achieve 
the same potential benefit from physical exercise as do 
patients who are not taking beta-blockers. The difference in 
the HDL cholesterol values cannot, therefore, be explained 
by failure of Group 1 patients to achieve exercise condition-
ing. 
Mechanism of lipid changes. The mechanism whereby 
.exercise and nonselective beta-blockers alter HDL choles-
terol and triglyceride levels is not clear. Both affect lipopro-
tein lipase, an enzyme that is responsible for catabolism of 
triglyceride-rich lipoproteins by means of beta]- and beta2-
adrenoreceptor activation (2,34,35). The surge of catechol-
amines during exercise increases lipoprotein lipase activity. 
In turn, the transfer of cholesterol to HDL lipoprotein is 
accelerated as plasma triglycerides are catabolized (36). 
Beta-adrenoceptor blockade produces just the opposite ef-
fect (27,37). Perhaps the beta-agonistic effects of chronic 
exercise override the beta-blocking activity of nonselective 
agents to account for the improvement of HDL cholesterol 
levels seen in the present study. Catecholamine-induced 
changes, however, are usually only transient. High density 
lipoprotein cholesterol may return to normal within 15 min 
after recovery from strenuous exercise, as catecholamine 
and lipoprotein lipase levels return to normal (38). Further-
more, we found that HDL cholesterol increased independent 
of triglyceride changes. Both of these factors argue against 
the explanation that lipoprotein lipase is the common de-
nominator for the opposing action of exercise and beta-
blockers on lipoproteins. 
In addition to its effect on lipoprotein lipase, physical 
exercise increases lecithin-cholesterol acyltransferase 
(LeAT). Lecithin-cholesterol acyltransferase is an enzyme 
found in apoprotein AI, which converts nascent plasma 
HDL cholesterol to mature HDL cholesterol through ester-
ification of cholesterol (39). Mature HDL cholesterol is 
responsible for transport of cholesterol to the liver, where it 
is removed from the circulation. Nonselective beta-blockers, 
on the other hand, decrease the activity of LCAT (40). 
Although there are no studies that have compared the 
relative importance of exercise versus beta-blockers with 
respect to the change in LCAT, it may be that the beneficial 
effect of exercise predominates over the negative influence 
of beta-blockers so that the net result is an elevation in 
LCAT. 
Finally, there are several as yet unexplored pathways 
that may help to explain the opposing effects of exercise and 
beta-blockers on serum lipids. Alpha- as well as beta-cell 
receptor activity may be different during physical condition-
ing than after administration of beta-blockers. Both types of 
receptors influence lipid and lipoprotein levels (41). Liver 
perfusion may be significantly different in conditioned pa-
JACC Vol. 12, No.3 
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tients as opposed to those taking a beta-blocking drug. How 
this modifies the synthesis of very low density lipoproteins 
and the clearance of HDL cholesterol lipoproteins is un-
known. 
Limitations of the study. Patients taking a beta-blocking 
drug (Group 1) started at a lower HDL cholesterol level than 
did those who were not receiving a beta-blocker (Group 2). 
Consequently, the final HDL cholesterol level after exercise 
for high risk Group 1 patients (35.8 ± 11 mg/dl) still places 
these patients at high risk for coronary artery events accord-
ing to the Framingham study (3). Nevertheless, as shown in 
the National Heart, Lung, and Blood Institute's type II 
coronary intervention study (42), a 10% increase in HDL 
cholesterol significantly reduces the progression of coronary 
artery lesions seen on angiography. Risk reduction, then, 
would probably occur in this group, although it is unclear to 
what degree. In addition, the present study was designed for 
12 weeks of exercise. It is possible that over a longer period 
of exercise, HDL cholesterol levels may reach higher levels. 
In Group 1 patients taking a beta-blocker who had a 
normal preexercise HDL cholesterol level, this level tended 
to decrease after exercise (p = NS). In contrast, the HDL 
cholesterol level tended to increase in Group 2 patients who 
had a normal preentry level (p > 0.05). Although it is 
possible that the decrease in HDL cholesterol levels for this 
subgroup of patients receiving a beta-blocker may represent 
an adverse drug effect, the downward trend may indicate 
only that a state of equilibrium had not been reached in 
patients recently started on medication. It has not been 
clearly established when HDL cholesterol levels reach a 
plateau after the start of nonselective beta-blocking therapy 
because the duration of most studies describing the effect of 
beta-blockers on the lipid profile has ranged from 4 weeks to 
6 months (16,43-45). 
Six patients were taking a calcium channel blocking 
medication (diltiazem) during the exercise study. According 
to previous reports (46,47), diltiazem does not adversely 
affect HDL cholesterol values, and we felt justified in 
including these patients in our study. One patient in Group 2 
began treatment with a diuretic late in the course of his 
exercise program. Because it is unlikely that the diuretic 
unfavorably altered the serum lipids by virtue of its late 
administration, and because aerobic training and diet control 
can modify the adverse effects ofthiazides on lipids (48), this 
patient was also kept in the study. 
We cannot draw any conclusions as to the effect of 
exercise on plasma lipid levels in female patients who are 
taking a beta-adrenergic blocking drug. Prospective studies 
on exercise and lipid changes in women indicate that HDL 
cholesterol levels do not change after exercise (7,49). On the 
other hand, most studies in men have shown a consistent 
increase in HDL cholesterol after or during exercise 
(7,24,33). 
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